Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: the Rotterdam study
Authors' conclusion
Lp(a) distributions and MACE rates substantially vary across high-risk groups in the general population.
Study context
- Population
- Rotterdam Study participants, including high-risk groups (atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), subclinical atherosclerosis, calcific aortic valve disease)
- Participants
- 5,129 participants
- Exposure
- ASCVD vs aortic valve calcification (AVC) score >300
Methodological detailspopulation-based
- Population-based
Main finding
As reported in the abstract
Prevalence of Lp(a) above trial thresholds and NNS
| Group | Lp(a) >150 nmol/L | Lp(a) >200 nmol/L | Numbers needed to screen (NNS) >150 nmol/L | NNS >200 nmol/L | NNS |
|---|---|---|---|---|---|
| ASCVD | 13.5% (11.9-15.3%) | 6.5% (5.3-7.8%) | 7.4 | 15.4 | |
| AVC score >300 | 20.2% (13.0-27.4) | 11.8% (6.6-19.0) | 5.0-8.5 |
Lp(a) >150 nmol/L
ASCVD13.5% (11.9-15.3%)
AVC score >30020.2% (13.0-27.4)
Lp(a) >200 nmol/L
ASCVD6.5% (5.3-7.8%)
AVC score >30011.8% (6.6-19.0)
Numbers needed to screen (NNS) >150 nmol/L
ASCVD7.4
AVC score >300Not reported in the abstract
NNS >200 nmol/L
ASCVD15.4
AVC score >300Not reported in the abstract
NNS
ASCVDNot reported in the abstract
AVC score >3005.0-8.5
Observational data: associations, not effects.
Further findings
Major adverse cardiovascular event (MACE) rates
- MACE rates varied by group and increased progressively with higher Lp(a) thresholds
Original publication
Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: the Rotterdam study. Eur J Prev Cardiol. Published 31 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it